Integrated Filing — IndAS



General information about company
Scrip Code 000000
NSE Symbol BALAXI
MSEI Symbol NOTLISTED
ISIN INE618N01022
Name of company BALAXI PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment SPECIALIZED WHOLESALE
Start date and time of board meeting 30-May-2025   11:10:00
End date and time of board meeting 30-May-2025   14:55:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2023-08-03
Indicate Company website link for updated RPT policy of the Company https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 96489000 609882000
Other income 3209000 53734000
Total income 99698000 663616000
2 Expenses
(a) Cost of materials consumed 82209000 509416000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0 0
(d) Employee benefit expense 13424000 48714000
(e) Finance costs 6933000 20577000
(f) Depreciation, depletion and amortisation expense 1115000 4560000
(f) Other Expenses
1 Administrative Expenses 7392000 27472000
Total other expenses 7392000 27472000
Total expenses 111073000 610739000
3 Total profit before exceptional items and tax -11375000 52877000
4 Exceptional items 0 0
5 Total profit before tax -11375000 52877000
6 Tax expense
7 Current tax 799000 17820000
8 Deferred tax -389000 -956000
9 Total tax expenses 410000 16864000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -11785000 36013000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -11785000 36013000
17 Other comprehensive income net of taxes 0 0
18 Total Comprehensive Income for the period -11785000 36013000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 110415000 110415000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 1168112000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.21 0.65
Diluted earnings (loss) per share from continuing operations -0.21 0.65
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.21 0.65
Diluted earnings (loss) per share from continuing and discontinued operations -0.21 0.65
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 66741000
Capital work-in-progress 220713000
Investment property
Goodwill 0
Other intangible assets 0
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method 250723000
Non-current financial assets
Non-current investments 0
Trade receivables, non-current
Loans, non-current 0
Other non-current financial assets 10235000
Total non-current financial assets 10235000
Deferred tax assets (net)
Other non-current assets
Total non-current assets 548412000
2 Current assets
Inventories 5000
Current financial asset
Current investments 0
Trade receivables, current 899220000
Cash and cash equivalents 286840000
Bank balance other than cash and cash equivalents 46000
Loans, current 787000
Other current financial assets 9144000
Total current financial assets 1196037000
Current tax assets (net)
Other current assets
Total current assets 1196042000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1744454000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 110415000
Other equity 1168112000
Total equity attributable to owners of parent 1278527000
Non controlling interest
Total equity 1278527000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total non-current financial liabilities 0
Provisions, non-current 1285000
Deferred tax liabilities (net) 8998000
Deferred government grants, Non-current
Other non-current liabilities 18010000
Total non-current liabilities 28293000
Current liabilities
Current financial liabilities
Borrowings, current 303797000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 75863000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 13694000
Total Trade payable 89557000
Other current financial liabilities
Total current financial liabilities 393354000
Other current liabilities 28140000
Provisions, current 0
Current tax liabilities (Net) 16140000
Deferred government grants, Current
Total current liabilities 437634000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 465927000
Total equity and liabilites 1744454000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 52877000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 20577000
Adjustments for decrease (increase) in inventories 8387000
Adjustments for decrease (increase) in trade receivables, current -131612000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 11516000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 2449000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -34878000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 4560000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 6480000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -112521000
Net cash flows from (used in) operations -59644000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 16380000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -76024000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 51880000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 336000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 197629000
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -249845000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 27045000
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 164236000
Repayments of borrowings 0
Payments of lease liabilities 984000
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 19014000
Other inflows (outflows) of cash 852000
Net cash flows from (used in) financing activities 172135000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -153734000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -153734000
Cash and cash equivalents cash flow statement at beginning of period 440574000
Cash and cash equivalents cash flow statement at end of period 286840000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 P Murali & Co Yes 30-Nov-2025


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 11-Oct-2022
Amount Raised 47569225000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation false
Comments of the Audit Committee after review None
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 The proceeds of the preferential issue shall be utilized tonmeet the capital expenditure requirements to support thenconstruction of the Company’s first pharmaceuticalnformulation plant, being set up at Jadcherla, Hyderabad.nFurther, it may be utilized to meet working capitalnrequirements and general corporate purposes and may alsonutilize to undertake any additional business activities undernthe main objects clause of the Memorandum of Associationnof the Company. Not applicable 47569225000000 0 19886687853000 0


Signatory Details
Name of signatory Ashish Maheshwari
Designation of person Managing Director
Place Hyderabad
Date 30-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 76627000 0 0
2 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 46893000 0 0
3 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 20808000 0 0
4 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 7315000 0 0
5 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE NICARAGUA S, A. WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 3915000 0 0
6 BALAXI PHARMACEUTICALS LIMITED BALAXI GLOBAL DMCC WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 52412000 0 0
7 BALAXI GLOBAL DMCC BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 61221000 0 0
8 BALAXI GLOBAL DMCC BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 32086000 0 0
9 BALAXI GLOBAL DMCC BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 18054000 0 0
10 BALAXI GLOBAL DMCC BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 6093000 0 0
11 BALAXI GLOBAL DMCC BALAXI HEALTHCARE CENTRAFRIQUE SARL WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 0 0 0
12 BALAXI GLOBAL DMCC BALAXI HEALTHCARE ANGOLA LDA WHOLLY OWNED SUBSIDIARY Sale of goods or services 0 not applicable 332761000 0 0
13 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 248316000 163495000
14 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 197355000 212361000
15 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 109654000 103695000
16 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 74898000 47867000
17 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE NICARAGUA S, A. WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 3164000 7189000
18 BALAXI PHARMACEUTICALS LIMITED BALAXI GLOBAL DMCC WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 403626000 364614000
19 BALAXI GLOBAL DMCC BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 1471000 30480000
20 BALAXI GLOBAL DMCC BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 104437000 91851000
21 BALAXI GLOBAL DMCC BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 26668000 46836000
22 BALAXI GLOBAL DMCC BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 43375000 51002000
23 BALAXI GLOBAL DMCC BALAXI HEALTHCARE CENTRAFRIQUE SARL WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 60955000 0
24 BALAXI GLOBAL DMCC BALAXI HEALTHCARE ANGOLA LDA WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 1274464000 1458234000
25 BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 8218000 2316000
26 BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 18544000 0
27 BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 4805000 0
28 BALAXI GLOBAL DMCC BALAXI HEALTHCARE CENTRAFRIQUE SARL WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 24240000 0
29 BALAXI GLOBAL DMCC BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 38387000 39162000
30 BALAXI GLOBAL DMCC BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 24888000 29065000
31 BALAXI GLOBAL DMCC BALAXI HEALTHCARE ECUADOR WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 6255000 6255000
32 BALAXI HEALTHCARE DOMINICANA S.R.L BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 2184000 24657000
33 BALAXI HEALTHCARE DOMINICANA S.R.L BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 4162000 0
34 BALAXI HEALTHCARE DOMINICANA S.R.L BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 670000 0
35 BALAXI HEALTHCARE DOMINICANA S.R.L BALAXI HEALTHCARE NICARAGUA S, A. WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 2646000 0
36 BALAXI HEALTHCARE EL SALVADOR SA DE BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Any other transaction Balance due 0 not applicable 0 1784000 0
37 BALAXI PHARMACEUTICALS LIMITED BALAXI GLOBAL DMCC WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 247229000
38 BALAXI PHARMACEUTICALS LIMITED BALAXI HEALTHCARE ECUADOR WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 3494000
39 BALAXI GLOBAL DMCC BALAXI HEALTHCARE DOMINICANA S.R.L WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 1244000
40 BALAXI GLOBAL DMCC BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 44007000
41 BALAXI GLOBAL DMCC BALAXI HEALTHCARE HONDURAS S. DE R.L WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 855000
42 BALAXI GLOBAL DMCC BALAXI HEALTHCARE EL SALVADOR SA DE WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 171000
43 BALAXI GLOBAL DMCC BALAXI HEALTHCARE CENTRAFRIQUE SARL WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 0
44 BALAXI GLOBAL DMCC BALAXI HEALTHCARE ANGOLA LDA WHOLLY OWNED SUBSIDIARY Investment 0 not applicable 0 0 95498000
45 BALAXI PHARMACEUTICALS LIMITED Ashish Maheshwari MANAGING DIRECTOR Remuneration 4000000 not applicable 0 0 0
46 BALAXI PHARMACEUTICALS LIMITED Pranav Maheshwari SENIOR VICE PRESIDENT- BUSINESS DEVELOPMENT Remuneration 2000000 not applicable 0 0 0
47 BALAXI GLOBAL DMCC Paridhi Maheshwari HEAD- ALTERNATE CHANNELS Remuneration 3000000 not applicable 0 0 0
48 BALAXI GLOBAL DMCC Amol Anand Mantri CHIEF FINANCIAL OFFICER Remuneration 0 not applicable 0 0 0
49 BALAXI PHARMACEUTICALS LIMITED Mahesh Inani COMPANY SECRETARY Remuneration 200000 not applicable 0 0 0
50 BALAXI PHARMACEUTICALS LIMITED Mohith Kumar Khandelwal COMPANY SECRETARY Remuneration 870000 not applicable 0 0 0
51 BALAXI PHARMACEUTICALS LIMITED Ashish Maheshwari MANAGING DIRECTOR Any other transaction Balance due 204000 not applicable 0 0 0
52 BALAXI PHARMACEUTICALS LIMITED Minoshi Maheshwari DIRECTOR Any other transaction Balance due 1215000 not applicable 0 0 0
53 BALAXI PHARMACEUTICALS LIMITED Ashish Maheshwari MANAGING DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
54 BALAXI PHARMACEUTICALS LIMITED Minoshi Maheshwari DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
55 BALAXI PHARMACEUTICALS LIMITED Gandhi Gamji DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
56 BALAXI PHARMACEUTICALS LIMITED Kunal Mahendra Bhakta DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
57 BALAXI PHARMACEUTICALS LIMITED M Srinivas Rao DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
58 BALAXI PHARMACEUTICALS LIMITED Akshita Suranat DIRECTOR Any other transaction Balance due 100000 not applicable 0 0 0
59 BALAXI PHARMACEUTICALS LIMITED BALAXI FOUNDATION Society Formed by the Company Any other transaction Balance due 1291000 not applicable 0 0 0
Total value of transaction during the reporting period 658185000





Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 3056000
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 3056000